Results 171 to 180 of about 231,111 (314)

Revisiting the Immune Frontier in Soft Tissue Sarcomas. [PDF]

Curr Oncol Rep
Bilani N, Al Akoum N, Al-Marayaty R, Orlando S, Alexiev B, de Viveiros PH, Pollack SM.   +6 more
europepmc   +1 more source

Active immunotherapy in malignant melanoma. [PDF]

BMJ, 1978
M B, McIllmurray, W G, Reeves, M J, Langman, M, Deane, M J, Embleton   +4 more
openaire   +2 more sources

Remote‐Controllable Immune‐Priming Spot Formation Via Nanocomplexed Hydrogel‐Assisted Histotripsy: Immunoasis

Advanced Materials, EarlyView.
A novel immunotherapeutic strategy combines injectable, adjuvant‐loaded hydrogels with externally controlled histotripsy to create immune‐priming sites within tumors. This approach generates millimeter‐sized immune‐activated lesions with flexible, patient‐tailored treatment scheduling, enabling precise immune activation through tumor ablation‐mediated ...
Sung Hoon Kim, Wonseok Choi, Yurim Kim, Hyeongmin Kim, Gu Won Jeong, Hyewon Park, Inchan Youn, Yoon Park, Sungmin Han, Young‐Min Kim   +9 more
wiley   +1 more source

Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions. [PDF]

Front Immunol
Lian M, Zhang C, Li T, Wang A.
europepmc   +1 more source

Rethinking Extracellular Vesicle Signaling

Advanced Materials, EarlyView.
Extracellular vesicles enable cell communication beyond intracellular cargo delivery. This perspective highlights two plausible surface‐based signaling modes: “bind‐and‐stay” and “bind‐and‐leave.” Transient binding to multiple cells challenges the one‐vesicle‐one‐cell model.
Wojciech Chrzanowski, Joy Wolfram
wiley   +1 more source

DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. [PDF]

J Gastrointest Oncol
Ding Y, Qian H, Liu H, Zhang J, Zhang X, Wei J, Chen X, Xu H.   +7 more
europepmc   +1 more source

Efficacy and Safety Assessment of 5‐Fluorouracil, Irinotecan and Oxaliplatin‐Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy

Advanced Materials, EarlyView.
A novel FIRINOX‐loaded implant demonstrates controlled drug release, and potent therapeutic efficacy in pancreatic ductal adenocarcinoma mouse models with safety confirmed in a large‐animal pre‐clinical model. This innovative drug delivery platform offers a promising new treatment approach for non‐resectable, treatment‐resistant pancreatic cancer ...
Samantha J. Wade, Ashna A. Kumar, Samuel O. Nitschke, Paul Joyce, Elahe Minaei, Stephanie E. Reuter Lange, Chelsea Penney, Holly Warren, Ruby Shepherd, Jeremy N. Dinoro, Gordon G. Wallace, Anthony Dosseto, Sameera Ansar, Naila Islam, Alistair Lochhead, George Sharbeen, Phoebe A. Phillips, Morteza Aghmesheh, Wayne J. Hawthorne, Kara L. Vine‐Perrow   +19 more
wiley   +1 more source

Antigen specific active immunotherapy: lessons from the first decade

Swiss Medical Weekly, 2005
M Adamina
doaj   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0. [PDF]

J Immunother Cancer
McKay RR, Ajmera A, Atkins MB, Barata PC, Bergerot C, Bukavina L, Choueiri TK, Desai A, Hakimi AA, Poteat S, Powles T, Rini BI, Shuch B, Signoretti S, Siva S, Xu W, Yip W, Zhang T, Pal SK.   +18 more
europepmc   +1 more source

The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy [PDF]

, 2014
Breckpot, Karine, De Smedt, Stefaan, Dewitte, Heleen, Heirman, Carlo, Lentacker, Ine, Thielemans, Kris, Van Lint, Sandra   +6 more
core   +1 more source